Description

Eli Lilly and Company’s $6 Billion Product Revenue Jump Signals a New Growth Phase!

Eli Lilly and Company reported its third-quarter 2026 results reflecting continued revenue growth driven primarily by its cardiometabolic portfolio, particularly incretin therapies such as Mounjaro and Zepbound. Total revenue increased 39% year-over-year, reaching nearly $7 billion above Q3 2025 levels, with key product revenue rising by over $6 billion. The company raised its full-year revenue guidance to between $91 billion and $92 billion, attributing growth to robust demand in the U.S. tied to the Medicare GLP-1 Bridge Program and sustained international momentum. The GLP-1 Bridge Program expanded access to obesity treatments for approximately 20 million seniors, with over half a million prescriptions filled since launch. Though programs like Foundayo for obesity and type 2 diabetes are in their early stages of rollout internationally, initial adoption rates appear positive. Gross margin improved slightly to 84.4%, driven by favorable product mix and production efficiencies, despite downward pressure from pricing adjustments and rebates.